{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:16:26Z","timestamp":1761174986723,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cmi.2023.03.022","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:27:31Z","timestamp":1679444851000},"page":"823-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae"],"prefix":"10.1016","volume":"29","author":[{"given":"Romain","family":"Gueneau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.03.022_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.34067\/KID.0002472021","article-title":"Global perspective on kidney transplantation: United States","volume":"2","author":"Wang","year":"2021","journal-title":"Kidney 360"},{"key":"10.1016\/j.cmi.2023.03.022_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.11511017","article-title":"Secular trends in infection-related mortality after kidney transplantation","volume":"13","author":"Kinnunen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2023.03.022_bib3","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.022_bib4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1600-6143.2006.01700.x","article-title":"Acute pyelonephritis represents a risk factor impairing long-term kidney graft function","volume":"7","author":"Pell\u00e9","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.03.022_bib5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3109\/23744235.2015.1051107","article-title":"ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence","volume":"47","author":"Pilmis","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2023.03.022_bib6","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.022_bib7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/jac\/dkr167","article-title":"Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India","volume":"66","author":"Goel","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2023.03.022_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13520","article-title":"Efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)","volume":"23","author":"Pierrotti","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.022_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2023.03.022_bib10","first-page":"125","article-title":"Point\u2013counterpoint: the MERINO trial and what it should imply for future treatment of ESBL bacteremia","volume":"4","author":"Grant","year":"2019","journal-title":"J\u00a0Assoc Med Microbiol Infect Dis Can"},{"key":"10.1016\/j.cmi.2023.03.022_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmi.2022.08.007","article-title":"Shorter antibiotic courses in the immunocompromised: the impossible dream?","volume":"29","author":"Imlay","year":"2023","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:12Z","timestamp":1761118392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1198743X23001398"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.022","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}